PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's response to treatment.
PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing changes in tumor blood supply in patients receiving antiangiogenesis therapy.
Unspecified Adult Solid Tumor, Protocol Specific
Procedure: magnetic resonance imaging
Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18
|Study Design:||Primary Purpose: Diagnostic|
|Official Title:||The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature|
|Study Start Date:||October 1998|
|Primary Completion Date:||August 2008 (Final data collection date for primary outcome measure)|
- Evaluate the ability of positron emission tomography (PET) to assess the effect of therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume in patients enrolled on a treatment protocol evaluating a therapeutic modality effecting the tumor associated vasculature.
- Evaluate the ability of PET to assess the effects of this type of therapy regimen on tumor uptake of fluorodeoxyglucose in these patients.
- Evaluate the ability of magnetic resonance imaging (MRI) to assess the effects of therapy directed against the tumor vasculature on tumor blood flow and tumor vascular density in these patients.
- Compare the findings on PET and/or MRI with those obtained from conventional CT in this patient population.
OUTLINE: This is a diagnostic study conducted concurrently with a therapeutic modality study.
Patients have magnetic resonance imaging and/or positron emission tomography (PET) scans performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of therapy, and 6 weeks following the completion of therapy. Each scan requires about 1-3 hours. Patients receive up to 3 different PET scans including tumor blood flow scan with H2015, tumor blood volume scan with 11CO, and glucose uptake scan with fludeoxyglucose F 18.
PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 2 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00019565
|United States, Maryland|
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office|
|Bethesda, Maryland, United States, 20892-1182|
|Study Chair:||Steven K. Libutti, MD||NCI - Surgery Branch|